Clinical Trial: Study of URC102 to Assess the Safety and Efficacy in Gout Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients

Brief Summary: The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.

Detailed Summary:
Sponsor: JW Pharmaceutical

Current Primary Outcome:

• Trend of serum uric acid reduction rate (%) [ Time Frame: 2 weeks ]
• Trend of serum uric acid levels (mg/dL) [ Time Frame: 2 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: JW Pharmaceutical

Dates:
Date Received: September 16, 2015
Date Started: October 2015
Date Completion:
Last Updated: January 9, 2017
Last Verified: January 2017